MTOR and small cell lung carcinoma: Anti-angiogenic (bevacizumab, cediranib, sunitinib, pazopanib, vandetanib) drugs, mTOR (everolimus, temsirolimus), IGF1R (AMG479), HDAC (panobinostat, vorinostat), HSP90 (STA9090), Hedgehog (LY2940680), PARP (veliparib) inhibitors, anti-Bcl-2 compounds (oblimersen, AT-101), immunomodulating agents (ipilimumab) either alone or in combination with chemotherapy are in development for SCLC in different setting.